ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer AG (BAY.F) Seeks EU Approval of Xarelto for Pulmonary Embolism


4/12/2012 6:39:51 AM

Bayer AG (BAYN.XE) Thursday said it is seeking European marketing authorization for its anti-clotting pill Xarelto to treat pulmonary embolism which, if approved, would boost the potential blockbuster drug's use in the E.U. to four indications from just three at present. The filing "has the potential to further extend the benefits of rivaroxaban [marketed as Xarelto] to an even wider patient population," Bayer said in a statement. The filing is supported by a study that was presented in March involving some 4,800 patients with pulmonary embolism, a blood clot on the lung.

Read at Fox News
Read at News Release
Read at RTT News
Read at News Release
 
 Read Article at  Related Companies  News Categories
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES